Defective repair of DNA double-strand breaks and chromosome damage in fibroblasts from a radiosensitive leukemia patient

Autor: Badie C, Iliakis G, Nicolas Foray, Alsbeih G, Ge, Pantellias, Okayasu R, Cheong N, Ns, Russell, Ac, Begg, Cf, Arlett

Publikováno v: Europe PubMed Central

A radiation-sensitive fibroblast culture (180BR) established from an acute lymphoblastic leukemia patient who died following radiotherapy is defective in the repair of radiation-induced DNA double-strand breaks. The cells also show a reduced capacity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::53ae073f6351a30521f7bcd7e02a7c40
http://europepmc.org/abstract/med/7882314

Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).

Autor: Schröder CP; Department Medical Oncology, Netherlands Cancer Institute Amsterdam and University Medical Center Groningen, The Netherlands., van Leeuwen-Stok E; Dutch Breast Cancer Trialists' Research Group (BOOG), The Netherlands., Cardoso F; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal., Linderholm B; Department of Oncologym, Sahlgrenska University Hospital, Gothenburg, Sweden and Swedish Association of Breast Oncologists (SABO), Sweden., Poncet C; European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Wolff AC; Department of Medical Oncology, Johns Hopkins, Baltimore, MD, USA., Bjelic-Radisic V; Breast Unit, Helios University Clinic, Wuppertal, University Witten/Herdecke, Germany., Werutsky G; Latin American Cooperative Oncology Group, Porto Alegre, Brazil., Abreu MH; Department of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal., Bozovic-Spasojevic I; Department of Medical Oncology, Institute of Oncology and Radiology, Belgrade, Serbia., den Hoed I; Department of Medical Oncology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands., Honkoop AH; Department of Medical Oncology, Isala, Zwolle, The Netherlands., Los M; Department of Medical Oncology, St. Antonius Ziekenhuis, Utrecht, The Netherlands., Leone JP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Russell NS; Department of Radiotherapy, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Smilde TJ; Department of Medical Oncology, Jeroen Bosch Ziekenhuis's Hertogenbosch, The Netherlands., van der Velden AWG; Department of Medical Oncology, Martini Ziekenhuis, Groningen, The Netherlands., Van Poznak C; Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA., Vleugel MM; Department of Medical Oncology, Waterlandziekenhuis, Purmerend, The Netherlands., Yung RL; Department of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Coens C; European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Giordano SH; Department of Health Services Research and Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA., Ruddy KJ; Department of Oncology, Mayo Clinic, Rochester, MN, USA.

Publikováno v: The oncologist [Oncologist] 2023 Oct 03; Vol. 28 (10), pp. e877-e883.

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.

Autor: Vliek S; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Hilbers FS; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Mandjes I; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kessels R; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kleiterp S; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lips EH; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Mulder L; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kayembe MT; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Russell NS; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Vrancken Peeters MTFD; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Surgery, Amsterdam University Medical center, Amsterdam, The Netherlands., Holtkamp MJ; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schot M; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Baars JW; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Honkoop AH; Department of Internal Medicine, Isala Klinieken, Zwolle, The Netherlands., Vulink AJE; Division of Medical Oncology, Reinier de Graaf Hospital, Delft, The Netherlands., Imholz ALT; Department of Internal Medicine, Deventer Ziekenhuis, Deventer, The Netherlands., Vrijaldenhoven S; Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands., van den Berkmortel FWPJ; Department of Oncology, Zuyderland Medisch Centrum, Heerlen-Geleen, The Netherlands., Meerum Terwogt JM; Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands., Schrama JG; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands., Kuijer P; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van der Padt-Pruijsten A; Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands., Wesseling J; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Gilhuijs KGA; Image Sciences Institute, University Medical Center Utrecht, Utrecht, Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Nederlof P; Department of Molecular diagnostics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Linn SC; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. s.linn@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. s.linn@nki.nl.; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. s.linn@nki.nl.

Publikováno v: NPJ breast cancer [NPJ Breast Cancer] 2023 Sep 09; Vol. 9 (1), pp. 75. Date of Electronic Publication: 2023 Sep 09.

Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.

Autor: Krul IM; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Boekel NB; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kramer I; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Janus CPM; Department of Radiation Oncology, Erasmus University MC Cancer Institute, Rotterdam, The Netherlands., Krol ADG; Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands., Nijziel MR; Department of Hematology, Catharina Hospital, Eindhoven, The Netherlands., Zijlstra JM; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., van der Maazen RWM; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Roesink JM; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Jacobse JN; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schaapveld M; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schmidt MK; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Opstal-van Winden AWJ; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sonke GS; Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Russell NS; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Aleman BMP; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Leeuwen FE; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Publikováno v: Cancer [Cancer] 2022 Dec 15; Vol. 128 (24), pp. 4285-4295. Date of Electronic Publication: 2022 Oct 25.

Radiotherapy-Related Dose and Irradiated Volume Effects on Breast Cancer Risk Among Hodgkin Lymphoma Survivors.

Autor: Roberti S; Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Leeuwen FE; Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Ronckers CM; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany., Krul IM; Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Vathaire F; Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM U1018, Villejuif, France.; Research Department, Gustave Roussy, Villejuif, France.; University Paris Saclay, Villejuif, France., Veres C; University Paris Saclay, Villejuif, France.; Molecular Radiation Therapy and Therapeutic Innovation, INSERM U1030, Villejuif, France.; Radiation Oncology Department, Gustave Roussy, Villejuif, France., Diallo I; University Paris Saclay, Villejuif, France.; Molecular Radiation Therapy and Therapeutic Innovation, INSERM U1030, Villejuif, France.; Radiation Oncology Department, Gustave Roussy, Villejuif, France., Janus CPM; Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Aleman BMP; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Russell NS; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hauptmann M; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.

Publikováno v: Journal of the National Cancer Institute [J Natl Cancer Inst] 2022 Sep 09; Vol. 114 (9), pp. 1270-1278.